Top

Published in:

01-01-2012 | Review

Nanomedicine: evolutionary and revolutionary developments in the treatment of certain inflammatory diseases

Author: Istvan Szelenyi

Published in: Inflammation Research | Issue 1/2012

Abstract

Nanomedicine, although in a nascent stage of development at present, is already a reality. Several pharmaceutical products using this modern technology are already on the market. Nanotechnology offers many potential benefits to medical research. Nanoparticle-based drug carriers can increase the efficacy and safety of drugs by enhancing capacity, improving solubility, combining multiple drugs, protecting against metabolism, and controlling release. Nanoparticles can also form the basis of multifunctional drug delivery vehicles by combining targeting, imaging, and therapeutic moieties. Multifunctional nanoparticles have tremendous potential to treat human diseases. The use of non-viral carriers (nanoparticles) can also improve the cellular/nuclear uptake of corresponding nucleotides. Preclinical characterization of nanoparticles intended for medical applications is complicated—due to the variety of materials used, their unique surface properties, and multifunctional nature. It is hard to predict what precise course nanomedicine will take in years to come. It is, however, very likely that this relatively young research area will become a driving force behind a vast revolution in medical treatment.

Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–61.PubMedCrossRef

Cazzola M, Puxeddu E, Bettoncelli G, Novelli L, Segreti A, Cricelli C, Calzetta L. The prevalence of asthma and COPD in Italy: a practice-based study. Respir Med. 2011;105:386–91.PubMedCrossRef

Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol. 1999;82:233–48.PubMedCrossRef

Borchers AT, Keen CL, Cheema GS, Gershwin ME. The use of methotrexate in rheumatoid arthritis. Semin Arthritis Rheum. 2004;34:465–83.PubMedCrossRef

Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11(Suppl 1):S1.PubMedCrossRef

Yokoyama M, Okano T, Sakurai Y, Ekimoto H, Shibazaki C, Kataoka K. Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res. 1991;51:3229–36.PubMed

van Dalen EC, Michiels EM, Caron HN, Kremer LC (2010) Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 3:CD005006.

Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol. 2008;36:43–8.PubMedCrossRef

Jain KK. Advances in the field of nanooncology. BMC Med. 2010;8:83.PubMedCrossRef

10.

Horisawa E, Hirota T, Kawazoe S, Yamada J, Yamamoto H, Takeuchi H, Kawashima Y. Prolonged anti-inflammatory action of DL-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit. Pharm Res. 2002;19:403–10.PubMedCrossRef

11.

Koo OM, Rubinstein I, Onyüksel H. Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharm Res. 2011;28:776–87.PubMedCrossRef

12.

Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, Gomariz RP, Leceta J. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med. 2002;80:16–24.PubMedCrossRef

13.

Tseng CL, Wu SY, Wang WH, Peng CL, Lin FH, Lin CC, Young TH, Shieh MJ. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials. 2008;29:3014–22.PubMedCrossRef

14.

Chen ZH, Kim HP, Sciurba FC, Lee SJ, Feghali-Bostwick C, Stolz DB, Dhir R, Landreneau RJ, Schuchert MJ, Yousem SA, Nakahira K, Pilewski JM, Lee JS, Zhang Y, Ryter SW, Choi AM. Egr-1 regulates autophagy in cigarette smoke-induced chronic obstructive pulmonary disease. PLoS One. 2008;3(10):e3316.PubMedCrossRef

15.

Shieh YA, Yang SJ, Wei MF, Shieh MJ. Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano. 2010;4:1433–42.PubMedCrossRef

16.

Wang Z, Tiruppathi C, Cho J, Minshall RD, Malik AB. Delivery of nanoparticle: complexed drugs across the vascular endothelial barrier via caveolae. IUBMB Life. 2011;63:659–67.PubMedCrossRef

17.

Chrastina A, Massey KA, Schnitzer JE. Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3:421–37.PubMedCrossRef

18.

Kim SH, Bianco N, Menon R, Lechman ER, Shufesky WJ, Morelli AE, Robbins PD. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol Ther. 2006;13:289–300.PubMedCrossRef

19.

Bianco NR, Kim SH, Morelli AE, Robbins PD. Modulation of the immune response using dendritic cell-derived exosomes. Methods Mol Biol. 2007;380:443–55.PubMedCrossRef

20.

Higuchi Y, Kawakami S, Oka M, Yamashita F, Hashida M. Suppression of TNFalpha production in LPS induced liver failure in mice after intravenous injection of cationic liposomes/NFkappaB decoy complex. Pharmazie. 2006;61:144–7.PubMed

21.

Wijagkanalan W, Kawakami S, Higuchi Y, Yamashita F, Hashida M. Intratracheally instilled mannosylated cationic liposome/NFκB decoy complexes for effective prevention of LPS-induced lung inflammation. J Control Release. 2011;149:42–50.PubMedCrossRef

22.

Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, Nakase T, Seki H, Kato K, Kaneda Y, Ochi T. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum. 1999;42:2532–42.PubMedCrossRef

23.

Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol. 1998;101:S434–9.PubMedCrossRef

24.

Corren J. Intranasal corticosteroids for allergic rhinitis: how do different agents compare? J Allergy Clin Immunol. 1999;104:S144–9.PubMedCrossRef

25.

Stoeck M, Riedel R, Hochhaus G, Häfner D, Masso JM, Schmidt B, Hatzelmann A, Marx D, Bundschuh DS. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther. 2004;309:249–58.PubMedCrossRef

26.

TOXNET (Toxicology Data Network) (accessed on Aug 01, 2011, http://toxnet.nlm.nih.gov/).

27.

http://www.terrabase-inc.com/anti-inflamms.html (accessed on July 22, 2011).

28.

Crim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther. 2001;23:1339–54.PubMedCrossRef

29.

Block LH, Patel RN. Solubility and dissolution of triamcinolone acetonide. J Pharm Sci. 1973;62:617–21.PubMedCrossRef

30.

Borgström L, Bondesson E, Morén F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J. 1994;7:69–73.PubMedCrossRef

31.

Williams RO 3rd, Hu C. Influence of water on the solubility of two steroid drugs in hydrofluoroalkane (HFA) propellants. Drug Dev Ind Pharm. 2001;27:71–9.PubMedCrossRef

32.

Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf. 2000;23:11–33.PubMedCrossRef

33.

Kraft WK, Steiger B, Beussink D, Quiring JN, Fitzgerald N, Greenberg HE, Waldman SA. The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol. 2004;44:67–72.PubMedCrossRef

34.

Shrewsbury SB, Bosco AP, Uster PS. Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. Int J Pharm. 2009;365:12–7.PubMedCrossRef

35.

Williamson PA, Menzies D, Nair A, Tutuncu A, Lipworth BJ. A proof-of-concept study to evaluate the antiinflammatory effects of a novel soluble cyclodextrin formulation of nebulized budesonide in patients with mild to moderate asthma. Ann Allergy Asthma Immunol. 2009;102:161–7.PubMedCrossRef

36.

Tian G, Longest PW, Su G, Hindle M. Characterization of respiratory drug delivery with enhanced condensational growth using an individual path model of the entire tracheobronchial airways. Ann Biomed Eng. 2011;39:1136–53.PubMedCrossRef

37.

Jaques PA, Kim CS. Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women. Inhal Toxicol. 2000;12:715–31.PubMedCrossRef

38.

Rabe KF, Dent G. Theophylline and airway inflammation. Clin Exp Allergy. 1998;28(Suppl 3):35–41.PubMed

39.

Lee DW, Shirley SA, Lockey RF, Mohapatra SS. Thiolated chitosan nanoparticles enhance anti-inflammatory effects of intranasally delivered theophylline. Respir Res. 2006;7:112.PubMedCrossRef

40.

Sutherland ER, Crapo JD, Bowler RP. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD. 2006;3:195–202.PubMedCrossRef

41.

Krusic PJ, Wasserman E, Keizer PN, Morton JR, Preston KF. Radical reactions of c60. Science. 1991;254:1183–5.PubMedCrossRef

42.

Yudoh K, Karasawa R, Masuko K, Kato T. Water-soluble fullerene (C60) inhibits the development of arthritis in the rat model of arthritis. Int J Nanomedicine. 2009;4:217–25.PubMedCrossRef

43.

Pinney SP, Koller BS, Franz MR, Woosley RL. Terfenadine increases the QT interval in isolated guinea pig heart. J Cardiovasc Pharmacol. 1995;25:30–4.PubMedCrossRef

44.

Stampfl A, Maier M, Radykewicz R, Reitmeir P, Göttlicher M, Niessner R. Langendorff heart: a model system to study cardiovascular effects of engineered nanoparticles. ACS Nano. 2011;5:5345–53.PubMedCrossRef

45.

Sun W, Mao S, Shi Y, Li LC, Fang L. Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption. J Pharm Sci. 2011;100:3365–73.PubMedCrossRef

46.

Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L, Zhao W. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm. 2008;355:321–7.PubMedCrossRef

47.

Kim ST, Jang DJ, Kim JH, Park JY, Lim JS, Lee SY, Lee KM, Lim SJ, Kim CK. Topical administration of cyclosporin A in a solid lipid nanoparticle formulation. Pharmazie. 2009;64:510–4.PubMed

48.

Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007;340:126–33.PubMedCrossRef

49.

Bhavna , Ahmad FJ, Mittal G, Jain GK, Malhotra G, Khar RK, Bhatnagar A. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions. Eur J Pharm Biopharm. 2009;71:282–91.PubMedCrossRef

50.

Maynard AD, Warheit DB, Philbert MA. The new toxicology of sophisticated materials: nanotoxicology and beyond. Toxicol Sci. 2011;120(Suppl 1):S109–29.PubMedCrossRef

51.

Inoue K, Takano H, Yanagisawa R, Sakurai M, Ichinose T, Sadakane K, Yoshikawa T. Effects of nano particles on antigen-related airway inflammation in mice. Respir Res. 2005;6:106.PubMedCrossRef

52.

Dailey LA, Jekel N, Fink L, Gessler T, Schmehl T, Wittmar M, Kissel T, Seeger W. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol. 2006;215:100–8.PubMedCrossRef

Title: Nanomedicine: evolutionary and revolutionary developments in the treatment of certain inflammatory diseases
Author: Istvan Szelenyi
Publication date: 01-01-2012
Publisher: SP Birkhäuser Verlag Basel
Published in: Inflammation Research / Issue 1/2012
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-011-0393-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Nanomedicine: evolutionary and revolutionary developments in the treatment of certain inflammatory diseases

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Seasonal changes in activities of human neutrophils in vitro

Rosiglitazone, a PPAR-γ agonist, inhibits VEGF secretion by peripheral blood mononuclear cells and ROS production by human leukocytes

Di-(2-ethylhexyl) phthalate induces production of inflammatory molecules in human macrophages

C-reactive protein haplotypes and dispositional optimism in obese and nonobese elderly subjects

The effects of leflunomide on CD4+CD25+Foxp3+ T regulatory cells in mice receiving allogeneic bone marrow transplantation

Curcumin inhibits ox-LDL-induced MCP-1 expression by suppressing the p38MAPK and NF-κB pathways in rat vascular smooth muscle cells

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page